Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2014

View Archived Issues

Phase II results show vismodegib is well tolerated in patients with mPDA

Kissei gains approval for Savene in Japan

XBiotech launches phase II study in rare disorder pyoderma gangrenosum

AstraZeneca and Bristol-Myers Squibb Diabetes Alliance awards grant to ADA

Oryzon cleared to begin phase I/IIa trial of ORY-1001 in the U.K.

Researchers in the U.S. prepare new GWT1 inhibitors for fungal infections

Novel ALK/c-Met inhibitors disclosed by Concert Pharmaceuticals

Novel biomarkers for breast cancer prognosis identified and evaluated

Dart NeuroScience discloses novel PDE1B inhibitors

Inhibition of immune cell priming to ameliorate autoimmune inflammatory diseases

Scientists at Merck & Co. patent new SYK inhibitors

Development of a novel class of tau ligands for medical imaging of AD

Aniona prepares novel GABA(A) modulators

Researchers at Bristol-Myers Squibb design new monoclonal antibodies

NovoEight obtains Japanese approval

Giotrif approved in Japan for patients with NSCLC and EGFR mutation

FDA extends review of Trimel's NDA for CompleoTRT

Karyopharm targets PAK-4 in pancreatic cancer

Sovaldi approved in Europe for treatment of chronic HCV infection

Shire sells Dermagraft assets to Organogenesis

Kyowa Hakko Kirin obtains approval for new formulation of antiepileptic agent in Japan

Ariad's Iclusig now commercially available in U.S.

Acerta Pharma launches phase I trial of novel BTK inhibitor in CLL

Mitsubishi Tanabe files for use of Telavic in additional indication in Japan

Biocon launches biosimilar version of Herceptin in India

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...